Anthony David Baxter
Keine laufenden Positionen mehr
Profil
Anthony David Baxter was the founder of Pulmagen Therapeutics (Synergy) Ltd.
founded in 2000, where he held the title of Chief Executive Officer in 2004.
He was also the founder of Iksuda Therapeutics Ltd.
founded in 2012, where he held the title of Non-Executive Chairman.
Baxter's former jobs include Chief Executive Officer at Cyprotex Ltd., Chief Executive Officer at deltaDOT Ltd.
from 2005 to 2008, Executive Chairman at Equinox Pharma Ltd., and Principal at Glaxo Group Research Ltd.
Baxter's education includes a doctorate degree from the University of Salford.
Ehemalige bekannte Positionen von Anthony David Baxter
| Unternehmen | Position | Ende |
|---|---|---|
| CYPROTEX PLC | Vorstandsvorsitzender | 31.07.2017 |
deltaDOT Ltd.
 deltaDOT Ltd. Medical SpecialtiesHealth Technology deltaDOT Ltd. develops and commercializes technologies for the separation and analysis of biomolecules. It offers High Performance Capillary Electrophoresis and Conventional Capillary Electrophoresis, and analytical services and contract research. The company was founded by Stuart Hassard and John Hassard in 2000 and is headquartered in London, the United Kingdom. | Vorstandsvorsitzender | 01.03.2008 |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Vorstandsvorsitzender | 01.10.2004 |
| Oxford Asymmetry International Plc | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1999 |
| Glaxo Group Research Ltd. | Corporate Officer/Principal | - |
Ausbildung von Anthony David Baxter
| University of Salford | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Cyprotex Ltd.
 Cyprotex Ltd. Miscellaneous Commercial ServicesCommercial Services Cyprotex Ltd. provides pharmaceutical research and development services. It offers ADME and pharmacokinetic, Biosciences, in vitro skin and ocular testing, physicochemical profiling, in vitro toxicology, in silico prediction, and endocrine disruption. The company was founded by David Leahy in 1999 and is headquartered in Abingdon, the United Kingdom. | Commercial Services |
| Oxford Asymmetry International Plc | Process Industries |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
deltaDOT Ltd.
deltaDOT Ltd. Medical SpecialtiesHealth Technology deltaDOT Ltd. develops and commercializes technologies for the separation and analysis of biomolecules. It offers High Performance Capillary Electrophoresis and Conventional Capillary Electrophoresis, and analytical services and contract research. The company was founded by Stuart Hassard and John Hassard in 2000 and is headquartered in London, the United Kingdom. | Health Technology |
| Glaxo Group Research Ltd. | |
Equinox Pharma Ltd.
 Equinox Pharma Ltd. Pharmaceuticals: MajorHealth Technology Equinox Pharma Ltd. provides informatics products and services used in the discovery and development of drugs. Its services include input screening data, rule-based model, predict a ranked list of active compounds and data source services. The company was founded on November 20, 2002 by Stephen Howard Muggleton, Michael Joseph Ezra Sternberg and Paul Simon Freemont and is headquartered in London, the United Kingdom. | Health Technology |
Iksuda Therapeutics Ltd.
 Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Health Technology |
